Use of Baricitinib in Patients With Moderate to Severe Coronavirus Disease 2019
Boghuma K Titanji, Monica M. Farley, Ashish Mehta, Randi Connor‐Schuler, Abeer Moanna, Sushma K. Cribbs, Jesse O’Shea, Kathryn DeSilva, Bonnie Chan, Alex Edwards, Christina Gavegnano, Raymond F. Schinazi, Vincent C. Marconi
Abstract
Hyperinflammation is associated with increased mortality in coronavirus disease 2019 (COVID-19). In this retrospective, uncontrolled patient cohort with moderate -severe COVID-19, treatment with baricitinib plus hydroxychloroquine was associated with recovery in 11 of 15 patients. Baricitinib for the treatment of COVID-19 should be further investigated in randomized, controlled clinical trials.
Topics & Concepts
MedicineHydroxychloroquineCoronavirus disease 2019 (COVID-19)Retrospective cohort studySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakCoronavirusDiseaseCohortInternal medicineSeverity of illnessClinical trialRandomized controlled trialVirologyOutbreakInfectious disease (medical specialty)COVID-19 Clinical Research StudiesLong-Term Effects of COVID-19Pancreatitis Pathology and Treatment